EpiCast Report: Heart Failure – Epidemiology Forecasts to 2026

Summary

Heart failure (HF), also referred to as congestive cardiac failure, is a heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic needs of the body (AHA, 2015a). HF commonly occurs in people older than 50 years of age, and severity increases progressively with age (Mosterd and Hoes, 2007). The symptoms can develop quickly, such as in acute HF, at which time the patient needs to be hospitalized. However, in chronic HF (CHF), the symptoms develop gradually (NHS, 2014).

Eventually, without the heart’s pumping action to deliver oxygen and nutrient-rich blood to the cells, fatigue, shortness of breath, and coughing results. Even everyday activities such as walking, climbing stairs, or carrying weight can become tedious.

In the 7MM, it is forecast that the diagnosed incident cases of HF will increase from 1,990,569 cases in 2016 to 2,468,827 cases in 2026 at an annual growth rate (AGR) of 2.40%. The US had the highest number of diagnosed incident cases of HF in the 7MM in both 2016 and 2026, at 827,525 cases in 2016, and 1,081,878 cases in 2026.

In the 7MM, epidemiologists forecast that the diagnosed prevalent cases of CHF will increase from 14,403,423 cases in 2016 to 17,127,297 cases in 2026 at an AGR of 1.89%. The US had the highest number of diagnosed prevalent cases of CHF in the 7MM in both 2016 and 2026, at 5,816,242 cases in 2016, and 7,115,415 cases in 2026.

The report “EpiCast Report: Heart Failure – Epidemiology Forecasts to 2026” provides an overview of the risk factors, comorbidities, and the global trends for HF in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the diagnosed incident cases of HF, diagnosed incident cases of HF segmented by ejection fraction and ventricular dysfunction, acute HF hospitalizations, acute HF hospitalizations by worsening HF, advanced HF, and de novo HF, and acute HF hospitalization by patients admitted and discharged, hospital length of stay for acute HF hospitalization, diagnosed prevalent cases of chronic HF (CHF), and diagnosed prevalent cases of CHF segmented by ejection fraction.

Scope

– The Heart Failure (HF) EpiCast Report provides an overview of the risk factors and global trends of HF in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the diagnosed incident cases of HF, diagnosed incident cases of HF segmented by ejection fraction and ventricular dysfunction, acute HF hospitalizations, acute HF hospitalizations by worsening HF, advanced HF, and de novo HF, and acute HF hospitalization by patients admitted and discharged, hospital length of stay for acute HF hospitalization, diagnosed prevalent cases of chronic HF (CHF), and diagnosed prevalent cases of CHF segmented by ejection fraction. The diagnosed prevalent cases of CHF, CHF with REF, and CHF with PEF are further classified according to the New York Heart Association (NYHA) functional classes I-IV. The diagnosed incident cases of HF and diagnosed prevalent cases of CHF are segmented by age (at 10-year intervals, for ages 45 years and older) and sex.
– The HF epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
– The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

The Heart Failure EpiCast report will allow you to –
– Develop business strategies by understanding the trends shaping and driving the global HF market.
– Quantify patient populations in the global HF market to improve product design, pricing, and launch plans.
– Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for HF therapeutics in each of the markets covered.
– Understand HF cases patient distribution by ejection fraction and NYHA functional classes.